ORTHOPEDIATRICS CORP — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
OrthoPediatrics presented updated full-year 2026 guidance: revenue of $270.0–$273.0M (14–16% growth vs. FY2025's $236.3M), Adjusted EBITDA approximately $25.0M, and free cash flow breakeven. Year-to-date 2026 (9M): revenue $72.7M, Adjusted EBITDA $6.9M, with set deployment at $10.0M for full year. No material acquisitions, financing, or operational changes disclosed; this is a standard investor presentation update.
Why this rating
Guidance reaffirms modest growth trajectory. $271.5M revenue is ~$35M below prior-year $236M base—a decelerating growth rate. No transformational events. Routine investor communication for $362.5M market-cap company.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.